Bayer’s turnaround is real—but its debt still sets the clock

A better quarter is not the same thing as a repaired investment case. Bayer is beginning to look less like a company in free fall and more like one capable of stabilizing its operations. The problem is that its balance sheet and legal legacy are still moving on a slower, more expensive timetable.

The case for optimism has become easier to make. In the second quarter of 2026, Bayer reported sales of €10.87 billion, EBITDA before special items of €2.1 billion and net income of €219 million, after a loss in the year-earlier quarter, according to Börse Global. But core earnings per share fell 16.7 percent to €0.95. That combination is the whole Bayer debate in miniature: progress is visible, yet the financial repair is not complete.

Bayer is improving, but improvement is not yet deleveraging

The most important figure is not the quarterly sales rebound. It is the debt trajectory. Bayer reported net financial debt of €33.647 billion as of June 30, 2026, up 3.5 percent from March 31, as Bayer’s own release shows.

That increase matters because a turnaround financed by a heavier debt load has less room for disappointment. Management has pointed to a possible reduction in year-end net debt to €29 billion to €30 billion, helped by a planned €3.0 billion equity contribution connected with the Apollo agreement for the LARC business. The transaction was expected to close in the third quarter, but the documentation provided here does not establish its final status.

Our view is that investors should treat deleveraging as the scoreboard, not as a supporting statistic. Cost savings, better sales and a return to profitability are useful only if they eventually create cash that can reduce obligations. Bayer has also said that litigation payments could produce negative free cash flow in 2026, with one analysis estimating a possible cash-flow result as low as minus €2.5 billion. Until operating improvement survives those payments, the turnaround remains more promise than proof.

The legal cloud is smaller, not gone

The June 25, 2026 Supreme Court decision materially improved Bayer’s position in lawsuits alleging inadequate cancer warnings on glyphosate products. Yet the ruling did not cover every category of claim. Design-defect and negligence allegations remain, while a proposed class settlement worth up to $7.25 billion still required final court approval in the material supplied here.

That distinction is crucial. Markets tend to celebrate legal victories immediately and process their limits later. Bayer’s share price rose sharply after the Supreme Court ruling, and the stock later traded at €49.28, according to the August report from Börse Global. But a favorable ruling does not turn litigation into a closed account. It changes the range of possible outcomes; it does not eliminate the need to pay, negotiate or wait.

The scale of the legacy explains why. Bayer has already paid around $10 billion to settle lawsuits, while provisions for glyphosate litigation were recently close to €7 billion, according to Tagesschau. The company faced roughly 170,000 US claims in total, with 65,000 still open at the time of that report. Even if the legal direction is now more favorable, the remaining claims can continue to consume cash and management attention.

The operating recovery needs to outrun the liabilities

There are genuine reasons to believe Bayer can improve. Its pharmaceutical business has growth products: Nubeqa sales rose 57 percent in the first quarter of 2026 and Kerendia sales increased 84 percent, according to the documentation. Management expects medium-single-digit pharmaceutical growth from 2027 and aims for an operating margin approaching 30 percent by 2030. Bayer is also targeting annual savings of €2 billion from 2026 through changes to management layers and bureaucracy.

Those targets create upside, but they also create a timing test. A shareholder is not simply asking whether the businesses can grow. The harder question is whether growth arrives before legal settlements, interest costs and debt repayments absorb the benefits.

This is why the stock can look cheap and still be risky. A depressed valuation may reflect the possibility that litigation finally becomes manageable and debt begins to fall. But it may also reflect the market’s demand for compensation while those outcomes remain uncertain. In our view, calling Bayer a straightforward recovery story is premature. It is a leveraged recovery story with a legal option attached.

The stock is now a timetable, not just a valuation

Bayer’s investment case has become increasingly event-driven. Investors are watching operating results, the cash-flow path, the final handling of the proposed settlement and the company’s ability to execute its debt-reduction plans. A legal win can lift the shares quickly, but only sustained cash generation can make that move durable.

That changes how the company should be judged. The relevant question is not simply, “Will Bayer recover?” It is, “Will Bayer recover quickly enough?” If the answer is yes, the current attention may be justified: lower legal uncertainty, stronger operations and falling debt could reinforce one another. If the answer is no, shareholders may spend years waiting for an operating recovery that is repeatedly diverted toward old liabilities.

Our verdict is cautious rather than bearish. Bayer’s turnaround deserves more credit than it received during the worst of the litigation overhang, but the balance sheet still sets the clock. Until net debt is demonstrably falling and free cash flow is consistently positive after legal payments, the company belongs in the high-risk recovery category—not in the clean comeback category. The improving business is the reason to watch Bayer; the debt and legal legacy are the reason not to mistake progress for resolution.